Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;21(1):2463191.
doi: 10.1080/21645515.2025.2463191. Epub 2025 Feb 11.

Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines

Ariel Bardach  1 , Martin Brizuela  2 , Mabel Berrueta  3 , Agustín Ciapponi  4 , Juan M Sambade  2 , Jamile Ballivian  2 , Vanesa Ortega  3 , Noelia Castellana  2 , Daniel Comandé  2 , Edward P K Parker  5 , Beate Kampmann  6   7 , Katharina Stegelmann  2 , Xu Xiong  8 , Andy Stergachis  9 , Flor M Munoz  10 , Pierre Buekens  8 , Agustina Mazzoni  2
Affiliations

Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines

Ariel Bardach et al. Hum Vaccin Immunother. 2025 Dec.

Abstract

Chikungunya virus (CHIKV), transmitted through Aedes mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of vaccine platforms used in Chikungunya vaccines that have been applied in other vaccines, focusing on adverse events of special interest (AESI) in pregnant persons, children, and adolescents. A comprehensive overview of systematic reviews (SRs) was conducted. Results: Seven systematic reviews were included and complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), and COVID-19, which share platforms with Chikungunya vaccines, showed no significant increase in AESI. Moderate-to high-quality SRs supported favorable safety profiles. Vaccines sharing platforms with Chikungunya vaccines generally exhibit acceptable safety profiles in pregnant persons, children, and adolescents.

Keywords: Chikungunya; adverse events; children and adolescents; pregnant persons; vaccine platforms; vaccine safety.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
PRISMA 2020 study flow diagram.
See this image and copyright information in PMC

References

    1. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CHL, Sang R, Sergon K, Breiman R, Powers AM, et al. Tracking epidemic Chikungunya virus into the Indian Ocean from East Africa. J Gen Virol. 2008. Nov. 89(11):2754–12. doi:10.1099/vir.0.2008/005413-0. - DOI - PMC - PubMed
    1. Sagay AS, Hsieh SC, Dai YC, Chang CA, Ogwuche J, Ige OO, Kahansim ML, Chaplin B, Imade G, Elujoba M, et al. Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria. Int J Infect Dis. 2024. Feb. 139:92–100. doi:10.1016/j.ijid.2023.11.036. - DOI - PMC - PubMed
    1. Kiener M, Cudjoe N, Evans R, Mapp-Alexander V, Tariq A, Macpherson C, Noël T, Gérardin P, Waechter R, LaBeaud AD, et al. Factors associated with Chikungunya infection among pregnant women in Grenada, West Indies. Am J Trop Med Hyg. 2023. Jul 5. 109(1):123–125. doi:10.4269/ajtmh.23-0157. - DOI - PMC - PubMed
    1. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C.. Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol. 1971. Sep. 107(3):643–647. doi:10.4049/jimmunol.107.3.643. - DOI - PubMed
    1. Bharat Biotech International Limited . Clinical trial to evaluate the immunogenicity of chikungunya vaccine - NCT04603131. https://clinicaltrials.gov/study/NCT04603131. [accessed 2024 May 27] [Internet]. [cited 2024 Nov 12]. https://clinicaltrials.gov/study/NCT04603131].

Publication types